Back to School: How biopharma can reboot drug development. Access exclusive analysis here
BMTI will sell its remaining dental business to Sankyo's Luitpold Pharmaceuticals Inc. subsidiary for $40 million in cash.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury